Naratriptan



Naratriptan





(nar ah trip’ tan)

Amerge

PREGNANCY CATEGORY C


Drug Classes

Antimigraine drug (triptan)

Serotonin selective agonist


Therapeutic Actions

Binds to serotonin receptors to cause vascular constrictive effects on cranial blood vessels, causing the relief of migraine in selective patients; migraine is believed to be caused by vasodilation of cranial blood vessels in these patients.



Indications



  • Treatment of acute migraine attacks with or without aura



Available Forms

Tablets—1, 2.5 mg


Dosages

Adults

Single dose of 1 mg PO or 2.5 mg PO; may be repeated in 4 hr if needed. Do not exceed 5 mg/24 hr.

Pediatric patients

Safety and efficacy not established.

Patients with renal or hepatic impairment

Contraindicated in severe renal impairment (CrCl less than 15 mL/min) or severe hepatic impairment (Child-Pugh grade C). In mild or moderate renal or hepatic impairment, start with lowest dose and do not exceed 2.5 mg/24 hr.

Jul 21, 2016 | Posted by in NURSING | Comments Off on Naratriptan

Full access? Get Clinical Tree

Get Clinical Tree app for offline access